Back working full time in my Day JOB :(((. They need me :(( Sporadig trading for now
Followers | 141 |
Posts | 7,182 |
Boards Moderated | 1 |
Alias Born | 07/06/2006 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you bro.. Keep up the good work..
i think that they are playing it safe. Remember that white kid that killed not just 4 but 9 people praying, reciting and studying the bible inside the church.. what was he labeled, not a terrorist. Even the media did not gave it any thought at all..
Maybe now a days what to label is selective based on what is the mode of the nation.. Now they all care about the right for the same sex to get married
Really.. Wow.. Nice
nice. $LEXG
OCFN A/S is UNLIMITED....WOOOW
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10315472
yep, for such a large float, the 0.0001 disappeared with less than 100m volume, it does not make sense.. So just watch it for now see how it will play out.
>>> ARNH jut got NEWS,,.. And just 51 Million ask volume wiped out 0.0001..Keep Close Watch, looks like this stock may move fast
ARNH TURNS A MAJOR CORNER: WINS BOTH THE APPEAL AGAINST FIRST AIR GROUP AND ATTRACTS HIGHLY SUCCESSFUL BOARD MEMBERS.
Date : 30/06/2015 @ 09:07
Source : InvestorsHub NewsWire
Stock : The Automotive Resource Network Holdings, Inc. (PN) (ARNH)
Quote : 0.0001 0.0 (0.00%) @ 10:04
ARNH
http://ih.advfn.com/p.php?pid=nmona&article=67518664
Fort Lauderdale, FL -- June 30, 2015 -- InvestorsHub NewsWire -- The Automotive Resources Holding group has won their appeal, from being wrongly named in a lawsuit. ARNH was wrongly named in a lawsuit by First Air Group, Inc. located in the state of NY. The case was heard under the laws of the state of NY and ARNH was not dropped from the suit in the lower courts. ARNH later perfected an appeal to overturn the findings of the lower court on July 25, 2014 where the Court of Appeal found in favor of ARNH and dismissed the company from any and all liability on April 2, 2015.
In addition to winning the appeal and being exonerated from all liability stemming from the First Air lawsuit, the company has been actively forming a new Board of Directors. “As the incoming CEO, and the first member of the Board of Directors of the company. I would like to personally thank the continued efforts of prior management, Ms. Kathy Roberton, to be more precise. Without her, intimate knowledge of the case, and hands on expertise, this would never have been possible. Kathy has shown high integrity and much regard for all shareholders and has been working with me to resolve any issues within the company. ” Stated CEO Mark Solomon
More updates on the progress of the company will follow.
Mark S Solomon Esq.
CEO
954-463-6755
mark@marksolomonlaw.com
DISCLAIMER <<Caution Concerning Forward Looking Statements>>
This press release contains statements that are "Forward-Looking" in nature (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). All statements regarding the Company's financial position, potential, business strategy, plans and objectives for future operations are Forward-Looking statements. Many of these statements contain words such as "goal," "aims," "may," "expect," "believe," "intend," "anticipate," "estimate," "continue," "would," "exceed," "should," "steady," "plan," "potential," "dramatic," and variations of such words and similar expressions identify Forward-Looking statements, but their absence does not mean that a statement is not a Forward-Looking statement. Because Forward-Looking statements involve future risks and uncertainties, there are many factors that could cause actual results to differ materially from those expressed or implied. The Company cannot predict the actual effect these factors will have on its results and many of the factors and their effects are beyond the Company's control. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise. Given these uncertainties, you should not rely too heavily on these forward-looking statements.
>>> ARNH jut got NEWS,,.. And just 51 Million ask volume wiped out 0.0001..Keep Close Watch, looks like this stock may move fast
ARNH TURNS A MAJOR CORNER: WINS BOTH THE APPEAL AGAINST FIRST AIR GROUP AND ATTRACTS HIGHLY SUCCESSFUL BOARD MEMBERS.
Date : 30/06/2015 @ 09:07
Source : InvestorsHub NewsWire
Stock : The Automotive Resource Network Holdings, Inc. (PN) (ARNH)
Quote : 0.0001 0.0 (0.00%) @ 10:04
ARNH
http://ih.advfn.com/p.php?pid=nmona&article=67518664
Fort Lauderdale, FL -- June 30, 2015 -- InvestorsHub NewsWire -- The Automotive Resources Holding group has won their appeal, from being wrongly named in a lawsuit. ARNH was wrongly named in a lawsuit by First Air Group, Inc. located in the state of NY. The case was heard under the laws of the state of NY and ARNH was not dropped from the suit in the lower courts. ARNH later perfected an appeal to overturn the findings of the lower court on July 25, 2014 where the Court of Appeal found in favor of ARNH and dismissed the company from any and all liability on April 2, 2015.
In addition to winning the appeal and being exonerated from all liability stemming from the First Air lawsuit, the company has been actively forming a new Board of Directors. “As the incoming CEO, and the first member of the Board of Directors of the company. I would like to personally thank the continued efforts of prior management, Ms. Kathy Roberton, to be more precise. Without her, intimate knowledge of the case, and hands on expertise, this would never have been possible. Kathy has shown high integrity and much regard for all shareholders and has been working with me to resolve any issues within the company. ” Stated CEO Mark Solomon
More updates on the progress of the company will follow.
Mark S Solomon Esq.
CEO
954-463-6755
mark@marksolomonlaw.com
DISCLAIMER <<Caution Concerning Forward Looking Statements>>
This press release contains statements that are "Forward-Looking" in nature (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). All statements regarding the Company's financial position, potential, business strategy, plans and objectives for future operations are Forward-Looking statements. Many of these statements contain words such as "goal," "aims," "may," "expect," "believe," "intend," "anticipate," "estimate," "continue," "would," "exceed," "should," "steady," "plan," "potential," "dramatic," and variations of such words and similar expressions identify Forward-Looking statements, but their absence does not mean that a statement is not a Forward-Looking statement. Because Forward-Looking statements involve future risks and uncertainties, there are many factors that could cause actual results to differ materially from those expressed or implied. The Company cannot predict the actual effect these factors will have on its results and many of the factors and their effects are beyond the Company's control. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise. Given these uncertainties, you should not rely too heavily on these forward-looking statements.
>>Got ARNH scanner alert for Sudden VOLUME @0.0001..
Added to Watch
>>Got ARNH scanner alert for Sudden VOLUME @0.0001..
Added to Watch
>>>>>$LEXG @0.0006 ++20%..Add to watch..
Ask getting wiped fast
>>>>>$LEXG @0.0006 ++20%..Add to watch..
Ask getting wiped fast
Wow, it took almost s month to dump @0.0005... Link back..
Will see how far low they are planing to take it..
$TNKE
NEWS 06/12/2015: AmeraMex International Receives Rental Agreements for $200,000/Year and a Heavy Equipment Purchase Order for $180,000
http://www.otcmarkets.com/stock/AMMX/news/AmeraMex-International-Receives-Rental-Agreements-for--200-000-Year-and-a-Heavy-Equipment-Purchase-Order-for--180-000?id=107147&b=y
AmeraMex International Receives Rental Agreements for $200,000/Year and a Heavy Equipment Purchase Order for $180,000
Jun 12, 2015
OTC Disclosure & News Service
-
AmeraMex International Receives Rental Agreements for $200,000/Year and a Heavy Equipment Purchase Order for $180,000
CHICO, CA--(Marketwired - Jun 12, 2015) - AmeraMex International, Inc. (OTC PINK: AMMX), a provider of heavy equipment for logistics companies (stevedoring/shipping), infrastructure construction, logging and mining companies entered into a rent-to-purchase agreement with a container yard in Northern Calif.
Under the terms of the agreement, the customer will rent the loaded container handler for approximately $12,500 per month with the option to purchase for roughly $220,000. The customer uses the equipment to load containers on and off of trucks and rail cars -- significantly increasing turnaround time and money saving. A second rental agreement was signed with a California Army Base. Under the terms of the five-year rental agreement for diesel forklifts, AmeraMex will report revenues of $50,000 per year for the term of the rental agreement.
AmeraMex CEO Lee Hamre commented, "In addition to the new rental agreements, we have sold a number of large capacity forklifts totaling over $180,000. The second and third quarters are showing continued growth within our core business. I would like to mention that the quarterly revenue projections provided in our June 9, 2015 press release did not included potential revenue from the company's agreement with Niger."
About AmeraMex International
AmeraMex International sells, leases and rents heavy equipment to companies within four industries: construction (light and infrastructure), shipping logistics, mining and commercial farming. AmeraMex, with customers in the Americas, Africa, Asia and Eastern Europe, has over 30 years of experience in heavy equipment sales and service and inventories top-of-the-line equipment from manufacturers such as Taylor Machine Works Inc. and Terex Heavy Equipment. For more information visit the AmeraMex website, www.AMMX.net or www.hamreequipment.com.
Except for the historical information contained herein, statements discussing sales or revenue projections are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially from any forward-looking statements made herein.
Investor and Media Relations
McCloud Communications, LLC
Marty Tullio
Managing Member
Office: 949.632.1900
Email Contact
Copyright © 2015 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
NEWS 06/12/2015: AmeraMex International Receives Rental Agreements for $200,000/Year and a Heavy Equipment Purchase Order for $180,000
http://www.otcmarkets.com/stock/AMMX/news/AmeraMex-International-Receives-Rental-Agreements-for--200-000-Year-and-a-Heavy-Equipment-Purchase-Order-for--180-000?id=107147&b=y
AmeraMex International Receives Rental Agreements for $200,000/Year and a Heavy Equipment Purchase Order for $180,000
Jun 12, 2015
OTC Disclosure & News Service
-
AmeraMex International Receives Rental Agreements for $200,000/Year and a Heavy Equipment Purchase Order for $180,000
CHICO, CA--(Marketwired - Jun 12, 2015) - AmeraMex International, Inc. (OTC PINK: AMMX), a provider of heavy equipment for logistics companies (stevedoring/shipping), infrastructure construction, logging and mining companies entered into a rent-to-purchase agreement with a container yard in Northern Calif.
Under the terms of the agreement, the customer will rent the loaded container handler for approximately $12,500 per month with the option to purchase for roughly $220,000. The customer uses the equipment to load containers on and off of trucks and rail cars -- significantly increasing turnaround time and money saving. A second rental agreement was signed with a California Army Base. Under the terms of the five-year rental agreement for diesel forklifts, AmeraMex will report revenues of $50,000 per year for the term of the rental agreement.
AmeraMex CEO Lee Hamre commented, "In addition to the new rental agreements, we have sold a number of large capacity forklifts totaling over $180,000. The second and third quarters are showing continued growth within our core business. I would like to mention that the quarterly revenue projections provided in our June 9, 2015 press release did not included potential revenue from the company's agreement with Niger."
About AmeraMex International
AmeraMex International sells, leases and rents heavy equipment to companies within four industries: construction (light and infrastructure), shipping logistics, mining and commercial farming. AmeraMex, with customers in the Americas, Africa, Asia and Eastern Europe, has over 30 years of experience in heavy equipment sales and service and inventories top-of-the-line equipment from manufacturers such as Taylor Machine Works Inc. and Terex Heavy Equipment. For more information visit the AmeraMex website, www.AMMX.net or www.hamreequipment.com.
Except for the historical information contained herein, statements discussing sales or revenue projections are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially from any forward-looking statements made herein.
Investor and Media Relations
McCloud Communications, LLC
Marty Tullio
Managing Member
Office: 949.632.1900
Email Contact
Copyright © 2015 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Yep great letter to the shareholder. I like it..
$DIGX, price appreciation is coming.. And it trades thinly.
Yep great letter to the shareholder. I like it..
$DIGX, price appreciation is coming.. And it trades thinly.
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human Genetics - See more at: http://globenewswire.com/news-release/2015/06/08/742751/10137449/en/Fibrocell-and-Intrexon-Announce-Positive-in-vitro-Pre-Clinical-Data-for-FCX-007-for-the-Treatment-of-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-at-European-Society-of-Human-Ge.html#sthash.u1pFJX1c.dpuf
http://globenewswire.com/news-release/2015/06/08/742751/10137449/en/Fibrocell-and-Intrexon-Announce-Positive-in-vitro-Pre-Clinical-Data-for-FCX-007-for-the-Treatment-of-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-at-European-Society-of-Human-Ge.html)6/08/2015
$FCSC @ 5.91.. Looks like price appreciation is coming.. May be we will see $10 soon... Add it to your watch
EXTON, Pa. and GERMANTOWN, Md., June 8, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced positive in vitro pre-clinical data for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The data were presented in a poster entitled "Development of a Genetically-Modified Human Dermal Fibroblast for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)" at the European Society of Human Genetics (ESHG) Conference from June 6-9, 2015 in Glasgow, Scotland, United Kingdom.
RDEB is caused by a mutation of the COL7A1 gene—the gene which encodes for type VII collagen (COL7), a protein that forms anchoring fibrils to hold together the layers of skin. Without these fibrils, skin layers separate causing severe blistering, open wounds and scarring in response to any kind of friction, including normal daily activities like rubbing or scratching.
In vitro product development data showed that FCX-007 (genetically-modified human dermal fibroblast, collagen VII) expresses full-length COL7 and exhibits the proper trimeric form, size, and binding functionality characteristic of anchoring fibrils, which are missing or deficient in RDEB patients. By genetically modifying autologous fibroblasts, ex vivo, to produce COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of RDEB by providing high levels of COL7 to the affected areas, avoiding systemic treatment.
"We are encouraged by these data that underscore the potential for FCX-007 to become the first personalized gene therapy to treat the underlying cause of RDEB," said David Pernock, Chairman and Chief Executive Officer of Fibrocell. "More broadly, our progress with FCX-007 over the past 18 months is a testament to the efficiency of our gene therapy product engine and exemplifies ground-breaking possibilities for our pipeline of novel therapeutics."
The data presented at ESHG show FCX-007 cells were successfully produced on cGMP-scale by expanding lentivirus-collagen type VII-transduced (LV-COL7-transduced) RDEB patient fibroblasts from a biopsy sample. The results showed:
The integrated transgene copy number per cell was dose-dependent using a replication-defective, self-inactivating (SIN) lentiviral vector;
The COL7 expression from the FCX-007 cells was confirmed by three different analytical methods: qRT-PCR, immunofluorescence staining and ELISA;
The structure of the COL7 expressed by the FCX-007 cells was shown to be predominantly trimeric by immunoprecipitation/SDS-PAGE/Western blot analysis. Naturally-occurring COL7 primarily has this characteristic trimeric structure which is believed to be integral to the creation of anchoring fibrils of necessary strength; and
The COL7 produced from the FCX-007 cells was demonstrated to be functional by binding to Laminin 332 both in an in vitro binding assay and by correction of the hypermotility phenotype of RDEB cells in an in vitro migration assay. In normal skin, COL7 anchoring fibrils bind to Laminin 332, extracellular matrix proteins, and other collagens to mediate attachment of the dermis to the epidermis.
Preliminary two- and six-week toxicology results using FCX-007 cells in a human skin graft model demonstrated no findings of toxicology in RDEB human skin xenograft severe combined immunodeficiency (SCID) mice.
"These positive data from our product development program show the potential of FCX-007 as an autologous, genetically-modified fibroblast cell therapy designed to improve skin function in RDEB patients through restoration of type VII collagen levels," said John Maslowski, Vice President of Scientific Affairs at Fibrocell. "We are continuing to move toward human clinical trials by further confirming FCX-007's COL7 persistence, distribution, localization and toxicology in more advanced model systems."
Suma Krishnan, Senior Vice President, Product Development and Head of Intrexon's Human Therapeutics Division, added, "As the FCX-007 program progresses, we are seeing the synergy of Intrexon's advanced biological engineering capabilities and Fibrocell's proprietary autologous fibroblast technology materialize into a powerful therapeutic candidate. The cell-based treatment is designed to go beyond palliative care and improve the quality of life in patients with the devastating RDEB disease. We look forward to working with Fibrocell to advance this promising new therapy into clinical studies."
The poster is available in the "Publications" section of Fibrocell's website at: http://www.fibrocellscience.com/technology/publications/.
About FCX-007
FCX-007 is Fibrocell's novel gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a congenital and progressive orphan skin disease caused by the deficiency of the protein type VII collagen (COL7). FCX-007 is a gene-modified autologous fibroblast that encodes for COL7 and is being developed in collaboration with Intrexon. By genetically modifying autologous fibroblasts, ex vivo, to produce COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly to the affected areas, avoiding systemic treatment. The drug is currently in late stage pre-clinical development with an IND filing targeted for mid-2015.
About Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recessive dystrophic epidermolysis bullosa (RDEB) is the most severe form of dystrophic epidermolysis bullosa (DEB), a congenital, progressive, devastatingly painful and debilitating genetic disorder that leads to death. RDEB is caused by a mutation of the COL7A1 gene, the gene which encodes for type VII collagen, a protein that forms anchoring fibrils. Anchoring fibrils hold together the layers of skin, and without them, skin layers separate causing severe blistering, open wounds and scarring in response to any kind of friction, including normal daily activities like rubbing or scratching. Children who inherit the condition are often called "butterfly children" because their skin is as fragile as a butterfly's wings. There are approximately 1,100 – 2,500 RDEB patients in the U.S. Currently, there is no cure for RDEB and treatments address only the sequelae, including daily bandaging, hydrogel dressings, antibiotics, feeding tubes and surgeries.
About Fibrocell Science, Inc.
Fibrocell is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. For more information, visit www.fibrocellscience.com.
About Intrexon Corporation
Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.
Forward-Looking Statements
This press release contains, and our officers and representatives may from time to time make, statements that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, among others, statements we make regarding our development strategy, timing and potential advantages of our product candidates.
These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell's control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) uncertainties relating to the initiation and completion of clinical trials; and (ii) whether clinical trial results will validate and support the safety and efficacy of our product candidates, as well as those set forth under the caption "Item 1A. Risk Factors" in Fibrocell's most recent Form 10-K filing.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell's most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell's most recent annual report.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
Investor Contact:
Karen Casey
Fibrocell Science, Inc.
Tel: +1 (484) 713-6133
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Intrexon Corporation
Tel: +1 (561) 410-7052
- See more at: http://globenewswire.com/news-release/2015/06/08/742751/10137449/en/Fibrocell-and-Intrexon-Announce-Positive-in-vitro-Pre-Clinical-Data-for-FCX-007-for-the-Treatment-of-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-at-European-Society-of-Human-Ge.html#sthash.u1pFJX1c.dpuf
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
May/12/2015 News:
Fibrocell Science (FCSC) Announces Rare Pediatric Disease Designation for FCX-007
http://www.streetinsider.com/Corporate+News/Fibrocell+Science+(FCSC)+Announces+Rare+Pediatric+Disease+Designation+for+FCX-007/10553477.html
ERN is back at 5.8.. it was a great news and chart move..
<<< Link Back
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human Genetics - See more at: http://globenewswire.com/news-release/2015/06/08/742751/10137449/en/Fibrocell-and-Intrexon-Announce-Positive-in-vitro-Pre-Clinical-Data-for-FCX-007-for-the-Treatment-of-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-at-European-Society-of-Human-Ge.html#sthash.u1pFJX1c.dpuf
http://globenewswire.com/news-release/2015/06/08/742751/10137449/en/Fibrocell-and-Intrexon-Announce-Positive-in-vitro-Pre-Clinical-Data-for-FCX-007-for-the-Treatment-of-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-at-European-Society-of-Human-Ge.html)6/08/2015
$FCSC @ 5.91.. Looks like price appreciation is coming..
EXTON, Pa. and GERMANTOWN, Md., June 8, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced positive in vitro pre-clinical data for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The data were presented in a poster entitled "Development of a Genetically-Modified Human Dermal Fibroblast for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)" at the European Society of Human Genetics (ESHG) Conference from June 6-9, 2015 in Glasgow, Scotland, United Kingdom.
RDEB is caused by a mutation of the COL7A1 gene—the gene which encodes for type VII collagen (COL7), a protein that forms anchoring fibrils to hold together the layers of skin. Without these fibrils, skin layers separate causing severe blistering, open wounds and scarring in response to any kind of friction, including normal daily activities like rubbing or scratching.
In vitro product development data showed that FCX-007 (genetically-modified human dermal fibroblast, collagen VII) expresses full-length COL7 and exhibits the proper trimeric form, size, and binding functionality characteristic of anchoring fibrils, which are missing or deficient in RDEB patients. By genetically modifying autologous fibroblasts, ex vivo, to produce COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of RDEB by providing high levels of COL7 to the affected areas, avoiding systemic treatment.
"We are encouraged by these data that underscore the potential for FCX-007 to become the first personalized gene therapy to treat the underlying cause of RDEB," said David Pernock, Chairman and Chief Executive Officer of Fibrocell. "More broadly, our progress with FCX-007 over the past 18 months is a testament to the efficiency of our gene therapy product engine and exemplifies ground-breaking possibilities for our pipeline of novel therapeutics."
The data presented at ESHG show FCX-007 cells were successfully produced on cGMP-scale by expanding lentivirus-collagen type VII-transduced (LV-COL7-transduced) RDEB patient fibroblasts from a biopsy sample. The results showed:
The integrated transgene copy number per cell was dose-dependent using a replication-defective, self-inactivating (SIN) lentiviral vector;
The COL7 expression from the FCX-007 cells was confirmed by three different analytical methods: qRT-PCR, immunofluorescence staining and ELISA;
The structure of the COL7 expressed by the FCX-007 cells was shown to be predominantly trimeric by immunoprecipitation/SDS-PAGE/Western blot analysis. Naturally-occurring COL7 primarily has this characteristic trimeric structure which is believed to be integral to the creation of anchoring fibrils of necessary strength; and
The COL7 produced from the FCX-007 cells was demonstrated to be functional by binding to Laminin 332 both in an in vitro binding assay and by correction of the hypermotility phenotype of RDEB cells in an in vitro migration assay. In normal skin, COL7 anchoring fibrils bind to Laminin 332, extracellular matrix proteins, and other collagens to mediate attachment of the dermis to the epidermis.
Preliminary two- and six-week toxicology results using FCX-007 cells in a human skin graft model demonstrated no findings of toxicology in RDEB human skin xenograft severe combined immunodeficiency (SCID) mice.
"These positive data from our product development program show the potential of FCX-007 as an autologous, genetically-modified fibroblast cell therapy designed to improve skin function in RDEB patients through restoration of type VII collagen levels," said John Maslowski, Vice President of Scientific Affairs at Fibrocell. "We are continuing to move toward human clinical trials by further confirming FCX-007's COL7 persistence, distribution, localization and toxicology in more advanced model systems."
Suma Krishnan, Senior Vice President, Product Development and Head of Intrexon's Human Therapeutics Division, added, "As the FCX-007 program progresses, we are seeing the synergy of Intrexon's advanced biological engineering capabilities and Fibrocell's proprietary autologous fibroblast technology materialize into a powerful therapeutic candidate. The cell-based treatment is designed to go beyond palliative care and improve the quality of life in patients with the devastating RDEB disease. We look forward to working with Fibrocell to advance this promising new therapy into clinical studies."
The poster is available in the "Publications" section of Fibrocell's website at: http://www.fibrocellscience.com/technology/publications/.
About FCX-007
FCX-007 is Fibrocell's novel gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a congenital and progressive orphan skin disease caused by the deficiency of the protein type VII collagen (COL7). FCX-007 is a gene-modified autologous fibroblast that encodes for COL7 and is being developed in collaboration with Intrexon. By genetically modifying autologous fibroblasts, ex vivo, to produce COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly to the affected areas, avoiding systemic treatment. The drug is currently in late stage pre-clinical development with an IND filing targeted for mid-2015.
About Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recessive dystrophic epidermolysis bullosa (RDEB) is the most severe form of dystrophic epidermolysis bullosa (DEB), a congenital, progressive, devastatingly painful and debilitating genetic disorder that leads to death. RDEB is caused by a mutation of the COL7A1 gene, the gene which encodes for type VII collagen, a protein that forms anchoring fibrils. Anchoring fibrils hold together the layers of skin, and without them, skin layers separate causing severe blistering, open wounds and scarring in response to any kind of friction, including normal daily activities like rubbing or scratching. Children who inherit the condition are often called "butterfly children" because their skin is as fragile as a butterfly's wings. There are approximately 1,100 – 2,500 RDEB patients in the U.S. Currently, there is no cure for RDEB and treatments address only the sequelae, including daily bandaging, hydrogel dressings, antibiotics, feeding tubes and surgeries.
About Fibrocell Science, Inc.
Fibrocell is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. For more information, visit www.fibrocellscience.com.
About Intrexon Corporation
Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.
Forward-Looking Statements
This press release contains, and our officers and representatives may from time to time make, statements that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, among others, statements we make regarding our development strategy, timing and potential advantages of our product candidates.
These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell's control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) uncertainties relating to the initiation and completion of clinical trials; and (ii) whether clinical trial results will validate and support the safety and efficacy of our product candidates, as well as those set forth under the caption "Item 1A. Risk Factors" in Fibrocell's most recent Form 10-K filing.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell's most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell's most recent annual report.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
Investor Contact:
Karen Casey
Fibrocell Science, Inc.
Tel: +1 (484) 713-6133
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Intrexon Corporation
Tel: +1 (561) 410-7052
- See more at: http://globenewswire.com/news-release/2015/06/08/742751/10137449/en/Fibrocell-and-Intrexon-Announce-Positive-in-vitro-Pre-Clinical-Data-for-FCX-007-for-the-Treatment-of-Recessive-Dystrophic-Epidermolysis-Bullosa-RDEB-at-European-Society-of-Human-Ge.html#sthash.u1pFJX1c.dpuf
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
May/12/2015 News:
Fibrocell Science (FCSC) Announces Rare Pediatric Disease Designation for FCX-007
http://www.streetinsider.com/Corporate+News/Fibrocell+Science+(FCSC)+Announces+Rare+Pediatric+Disease+Designation+for+FCX-007/10553477.html
CYPW 5MILLION ASK BLOCK hit,,, just now.
>>>>VOLUME ALERT: $TALK...0.0002 got wiped in less than 30 min
Less than 30min of trading we have 493 million shares traded...
Looks like a hard runner, chart showing reversal from over sold...
KEEP IT ON CLOSE WATCH
>>>>VOLUME ALERT: $TALK...0.0002 got wiped in less than 30 min
Less than 30min of trading we have 493 million shares traded...
Looks like a hard runner, chart showing reversal from over sold...
KEEP IT ON CLOSE WATCH
Nice news...$AMMX
$ERHE @0.0022.. Now this is a thing of beauty
Congratulation all....
<<<< link Back and follow the moves
$ERHE @0.0022.. Now this is a thing of beauty from 0.0004/0.0003...
Congratulation all....
<<<< link Back and follow the moves
$ERHE @0.0022.. Now this is a thing of beauty from 0.0004/0.0003...
Congratulation all....
<<<< link Back and follow the moves
Wow bro,,, the only advice I am gonna give is, NEVER,,EVER,,EVER,,EVER invest your retirement money in ANY STOCK..I mean it, any stocks.
GLTY
Actually a shorty did a10K paint job @0.0013. What a pathetic desperate attempt..
Get ready Guys for Tomorrow.
$ERHE, about to have a wings.. Chart showing higher highs and higher lows.,, sweet..
0.0014 is shy today, maybe tomorrow
Yep, like 12 million shares block buys @0.0013... Holly Molly
$ERHE
>>>> SIPC @008..... Let keep watching see how low it can go..
Waiting on entry point...
<<<< Link Back
Tick Tock... Here we go...
$ERHE
Of course bro, just like the 8market maker wall @0.001 was real.. I trust your words
There was like 8 Market Maker sitting @0.001 with their fake ask.. and it disappeared so fast my eyes did not have a chance to blink ....
Let see how desperate they are gonna be..
$ERHE is about to pass 0.0014.. watch how quick the fake wall will disappear